このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

BioNTech マネジメント

マネジメント基準チェック /44

BioNTech'sの CEO はUgur Sahinで、 Jan2008年に任命され、の在任期間は 16.42年です。の年間総報酬は€ 3.06Mで、 22.9%給与と77.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の17.11%を直接所有しており、その価値は$ 3.65B 。経営陣と取締役会の平均在任期間はそれぞれ5.4年と4.2年です。

主要情報

Ugur Sahin

最高経営責任者

€3.1m

報酬総額

CEO給与比率	22.9%
CEO在任期間	16.4yrs
CEOの所有権	17.1%
経営陣の平均在職期間	5.4yrs
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

CEO報酬分析

BioNTech の収益と比較して、Ugur Sahin の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	€113m
Dec 31 2023	€3m	€700k	€930m
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€4b
Mar 31 2023	n/a	n/a	€6b
Dec 31 2022	€6m	€360k	€9b
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

報酬と市場: Ugurの総報酬 ($USD 3.28M ) は、 UK市場 ($USD 5.78M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Ugurの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Ugur Sahin (59 yo)

16.4yrs

在職期間

€3,056,000

報酬

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ugur Sahin	Co-Founder	16.4yrs	€3.06m	17.11% € 3.6b
Ozlem Tureci	Co-Founder	6.4yrs	€814.00k	0.38% € 78.8m
Jens Holstein	CFO & Member of Management Board	2.9yrs	€1.32m	0.00067% € 139.5k
Sierk Poetting	MD, COO & Member of Management Board	10.4yrs	€821.00k	0.31% € 65.1m
Ryan Richardson	Chief Strategy Officer	4.4yrs	€1.41m	0.0061% € 1.3m
Sean Marett	Chief Business Officer	12.4yrs	€133.00k	0.34% € 70.3m
James Timothy Ryan	Chief Legal Officer & Member of the Management Board	less than a year	€848.00k	データなし
Zach Taylor	Senior Vice President of Corporate Development & Strategy	less than a year	データなし	データなし
Katalin Kariko	Senior VP & External Consultant for RNA Protein Replacement Therapies	no data	データなし	データなし
Oliver Henning	Senior Vice President of Operations	no data	データなし	データなし
Sebastian Kreiter	Senior Vice President of Immunotherapy & Preclinical Research	no data	データなし	データなし
Siegbert Kloos	Senior Vice President of Global R&D Digital	no data	データなし	データなし

5.4yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: 0A3Mの経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Rudolf Staudigl	Supervisory Board Member	2yrs	€90.00k	0.00017% € 35.4k
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	6.4yrs	€114.00k	データなし
Michael Motschmann	Independent Supervisory Board Member	16.4yrs	€80.00k	データなし
Helmut Jeggle	Independent Supervisory Board Chairman	16.4yrs	€226.00k	0.14% € 28.7m
Nicola Blackwood	Member of Supervisory Board	1.1yrs	€46.00k	データなし
Anja Morawietz	Supervisory Board Member	2yrs	€105.00k	0.00010% € 20.8k

4.2yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: 0A3Mの取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

BioNTech マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE Approves Board Appointments

Recent updates

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023)

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022)

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

New minor risk - Shareholder dilution

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022)

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Investor sentiment improves as stock rises 16%

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings released: €0.79 loss per share (vs €6.86 profit in 2Q 2022)

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

BioNTech SE Provides Revenue Guidance for the Full Year 2023

Investor sentiment improves as stock rises 49%

Full year 2022 earnings released: EPS: €38.78 (vs €42.18 in FY 2021)

Investor sentiment deteriorated over the past week

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

Third quarter 2022 earnings released: EPS: €7.43 (vs €13.14 in 3Q 2021)

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Now 20% undervalued after recent price drop

Pfizer Inc. and BioNTech SE Receive Positive Chmp Opinion for Conversion of Comirnaty® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster in European Union

Biontech Presents Encouraging Phase 1/2 Follow-Up Data for Car-T Candidate Bnt211 in Hard-To-Treat Solid Tumors At ESMO

Pfizer Inc. and BioNTech SE Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months Through 4 Years of Age

Pfizer and Biontech Submits Application to U.S. FDA for Emergency Use Authorization of Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine

BioNTech Reiterates Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: €6.88 (vs €11.42 in 2Q 2021)

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy with Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design

Pfizer Inc. and BioNTech SE Submits Variation to the European Medicines Agency

Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine Comirnaty for Adolescents 12 Through 15 Years of Age

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Investor sentiment improved over the past week

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

BioNTech SE Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer

Pfizer and BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

Investor sentiment deteriorated over the past week

BioNTech SE Announces Positive Phase 1 Data from MRNA-Based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer Presented At ASCO

マネジメント基準チェック /44